Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
|
|
- Kevin Lang
- 5 years ago
- Views:
Transcription
1 bs_bs_banner doi: /jog J. Obstet. Gynaecol. Res. Vol. 40, No. 2: , February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke Aoki Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan Abstract We present the Patient Annual Report in 2011 and the Treatment Annual Report in 2005 that were collected and analyzed by the Japan Society of Obstetrics and Gynecology. Data on patients with cervical cancer, 7713 with endometrial cancer and 4672 with ovarian cancer in whom treatment was started in 2011 and data on the prognosis of 2985 patients with cervical cancer, 2812 with endometrial cancer, and 1839 with ovarian cancer who were started on treatment in 2005 were analyzed and summarized. Patient Annual Report in 2011: Stage 0 accounted for 58%, stage I for 24%, stage II for 9%, stage III for 5%, and stage IV for 4% of all the patients with cervical cancer. Stage 0 accounted for 6%, stage I for 61%, stage II for 8%, stage III for 18%, and stage IV for 7% of patients with endometrial cancer. Stage I accounted for 43%, stage II for 9%, stage III for 29%, and stage IV for 8% of patients with ovarian cancer. Treatment Annual Report in 2005: The 5-year overall survival rates of patients with cervical cancer were 91% in stage I, 78% in stage II, 57% in stage III, and 30% in stage IV. The 5-year overall survival rates of patients with endometrial cancer were 95% in stage I, 89% in stage II, 77% in stage III, and 23% in stage IV. The 5-year overall survival rates of patients with ovarian surface epithelialstromal tumors were 92% in stage I, 75% in stage II, 50% in stage III and 39% in stage IV. Key words: annual report, cervical cancer, endometrial cancer, gynecological cancer, Japan, ovarian cancer. Introduction The Japan Society of Obstetrics and Gynecology (JSOG) collects and analyzes annual data on the clinicopathologic factors and prognosis of gynecologic cancers from member institutions every year to investigate the trends in gynecologic cancers in Japan. Herein, we present the Patient Annual Report in 2011 and the Treatment Annual Report in (The data presented in this paper were quoted and modified from Acta Obstetrica et Gynaecologica Japonica 64 (12) , and Acta Obstetrica et Gynaecologica Japonica 65 (3) , ). Methods Data on patients in whom treatment was started in 2011 were collected, then were retrospectively analyzed and summarized in the Patient Annual Report in Data on the prognosis of patients who were started on treatment in 2005 were collected then were analyzed and summarized in the Treatment Annual Report in 2005, assuming that a 5-year follow-up period is necessary. This study was conducted with the approval of the ethics committee of JSOG. Patient Annual Report in 2011 The subjects included 9038 patients with stage 0 cervical cancer (carcinoma in situ), 6660 with stage I IV Received: November Accepted: November Reprint request to: Professor Daisuke Aoki, Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku , Tokyo, Japan. aoki@z7.keio.jp Daisuke Aoki, Chair of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology The Author
2 Annual report of gynecologic cancers in Japan cervical cancer, 440 with stage 0 endometrial cancer (atypical endometrial hyperplasia), 7273 with stage I IV endometrial cancer, 4672 with ovarian cancer, and 1420 with ovarian tumors of borderline malignancy in whom the diagnosis was made histopathologically in each of the 305 member institutions of JSOG and who were started on treatment between January and December Clinical stages for cervical cancer and surgical stages for endometrial and ovarian cancer, including borderline malignancy, were based on the International Federation of Obstetricians and Gynaecologists (FIGO) 1988 staging system. Data on the age, clinical stage, histological type, and treatment were collected for patients with cervical cancer. Data on the age, surgical stage, histological type, and treatment were collected for patients with endometrial cancer patients. Data on the age, surgical stage, histological type and treatment were collected for the patients with ovarian cancer and ovarian tumors of borderline malignancy. Patient information was anonymized in a linkable fashion and then the patient information was registered on the website of JSOG from each institution. After two or more members of the Committee on Gynecologic Oncology checked the integrity of the collected data, the data were statistically analyzed. Treatment Annual Report in 2005 In all, 218 institutions collected data on the 3-year and 5-year prognoses of patients registered in any of the member institutions of JSOG between January and December 2005 and reported in the Patient Annual Report in The patients in the 218 institutions included 5083 with cervical cancer, 4266 with endometrial cancer, and 3066 with ovarian cancer. Data from institutions in which 20% or more of the registered patients were untraceable were not included in the analysis of the treatment outcome and the prognosis, because such data would reduce the reliability of the treatment outcome and the prognosis. Accordingly, the data of 2985 patients with cervical cancer, 2812 with endometrial cancer, and 1839 with ovarian cancer were included in the analysis of the treatment outcome and the prognosis. Personal information was anonymized in a linkable fashion and then information on the prognosis was registered on the website of JSOG. Thereafter, the data were statistically analyzed at the Biostatistics Center, Kurume University. Statistical analysis Overall survival rates were analyzed by the Kaplan Meier method, and statistical significance was determined using the log rank test. Results Patient Annual Report in Cervical cancer Age distribution (Fig. 1). Patients aged 40 49, 30 39, and years accounted for 24.8%, 20.2% and 18.4% of all the registered cases, respectively, showing that the disease predominantly affected women in their 40s. Stages (Fig. 2). Stage 0 accounted for 57.6%, stage I for 24.1% (stage Ia1, 6.0%; stage Ia2, 0.7%; stage Ib1, Figure 1 Age distribution of patients with stage I IV cervical cancer by clinical stage in 2011., stage I;, stage II;, stage III;, stage IV. Figure 2 Distribution of clinical stages in patients with cervical cancer in *Subclassification unknown The Author 339
3 D. Aoki 12.5%; stage Ib2, 3.5%; subclassification unknown, 1.4%), stage II for 9.4% (stage IIa, 2.6%; stage IIb, 6.8%; subclassification unknown, 0%), stage III for 4.9% (stage IIIa, 0.6%; stage IIIb, 4.3%; subclassification unknown, 0%), and stage IV for 4.1% (stage IVa, 1.1%; stage IVb, 3.0%; subclassification unknown, 1.1%) of all the patients. Histological types (Table 1). Squamous cell carcinoma was the most commonly encountered histopathologic type, accounting for 73.9% of all cases; adenocarcinoma accounted for 23.7% of all cases. The other rare histological types encountered are shown in Table 1. Treatment (Fig. 3). Of the patients, 37.8% underwent surgery alone, 20.2% received chemotherapy and other therapies in addition to radiotherapy, 13.4% received chemotherapy and other therapies in addition to surgery, 11.7% received radiotherapy alone, and 5.3% received radiotherapy in addition to surgery. Other therapies shown in the figure include immunotherapy and hormone therapy. 2. Endometrial cancer Age distribution (Fig. 4). Patients aged 50 59, 60 69, and years accounted for 30.1%, 28.9%, and 15.7%, respectively, of all cases, showing that the disease predominantly affected women in their 50s. On the other hand, patients aged younger than 40 years accounted for only 5.5% of all the cases. Surgical stages (Fig. 5). Stage 0 accounted for 5.7%, stage I for 60.6% (stage Ia, 18.9%; stage Ib, 29.6%; stage Ic, 11.8%; subclassification unknown, 0.3%), stage II for 8.1% (stage IIa, 3.1%; stage IIb, 4.6%; subclassification unknown, 0.4%), stage III for 18.4% (stage IIIa, 9.4%; stage IIIb, 0.4%; stage IIIc, 7.6%; subclassification unknown, 1.0%), and stage IV for 7.2% (stage IVa, 0.3%; stage IVb, 6.6%; subclassification unknown, 0.3%) of all the patients. Figure 3 Distribution of treatment methods in patients with cervical cancer by clinical stage in 2011., stage I;, stage II;, stage III;, stage IV. Figure 4 Age distribution of patients with stage I IV endometrial cancer by surgical stage in 2011., stage I;, stage II;, stage III;, stage IV. Figure 5 Distribution of surgical stages in patients with endometrial cancer in *Subclassification unknown The Author
4 Annual report of gynecologic cancers in Japan Table 1 Histological types of cervical cancer in 2011 Histological type No. of % patients Squamous cell carcinoma, classification unknown Squamous cell carcinoma, keratinizing type Squamous cell carcinoma, non-keratinizing type Adenocarcinoma, classification unknown Mucinous adenocarcinoma, endocervical type Mucinous adenocarcinoma, intestinal type Endometrioid adenocarcinoma Clear cell adenocarcinoma Serous adenocarcinoma Mesonephric adenocarcinoma Adenosquamous carcinoma Glassy cell carcinoma Adenoid cystic carcinoma Adenoid basal cell carcinoma Carcinoid Small cell carcinoma Undifferentiated carcinoma Carcinosarcoma Others Unknown (samples not taken) Total 6660 Table 2 Histological types of endometrial cancer in 2011 Histological type No. of % patients Endometrioid carcinoma Endometrioid adenocarcinoma Adenosquamous carcinoma Adenoacanthoma Serous adenocarcinoma Clear cell adenocarcinoma Mucinous adenocarcinoma Squamous cell carcinoma Mixed carcinoma Undifferentiated carcinoma Carcinofibroma Carcinosarcoma Classification unknown Total 7273 Histological types (Table 2). Endometrioid carcinoma was the most common, accounting for 83.1% of all the tumors. Other histological types included serous adenocarcinoma (4.6%), clear cell adenocarcinoma (2.4%), and mixed carcinoma (2.2%). Carcinosarcoma was observed in 5.0% of the patients. Treatment (Fig. 6). Of the patients, 54.4% underwent surgery alone, 38.6% received chemotherapy and other therapies, such as hormone therapy after surgery, and 1.2% received radiotherapy after surgery. Other therapies shown in the figure include immunotherapy. 3. Ovarian cancer Age distribution (Fig. 7). Patients aged 60 69, 50 59, and years accounted for 27.2%, 25.1%, and 20.0%, respectively, of all the cases, showing that the disease predominantly affected women in their 50s and 60s. Surgical stages (Fig.8). Stage I accounted for 43.0% (stage Ia, 16.6%; stage Ib, 0.8%; stage Ic, 25.6%), stage II for 8.9% (stage IIa, 0.8%; stage IIb, 0.9%; stage IIc, 7.1%), stage III for 29.3% (stage IIIa, 1.1%; stage IIIb, 3.9%; stage IIIc, 24.3%), and stage IV for 8.0% of all the patients. Neoadjuvant chemotherapy was given to 10.6% of the patients. Histological types (Table 3). Surface epithelial-stromal tumors accounted for 92.4%: serous adenocarcinoma accounted for 32.7%, clear cell adenocarcinoma for 23.7%, endometrioid adenocarcinoma for 16.2%, and mucinous adenocarcinoma for 11.8% of all the tumors. Sex cord-stromal and germ cell tumors were observed in 0.2% and 4.3% of the patients, respectively. Treatment (Fig.9). Of the patients, 78.2% received chemotherapy after surgery, 19.3% underwent surgery alone, and 1.7% received chemotherapy alone The Author 341
5 D. Aoki Figure 6 Distribution of treatment methods in patients with endometrial cancer by surgical stage in 2011., stage I;, stage II;, stage III;, stage IV. Figure 7 Age distribution of patients with ovarian cancer by surgical stage in 2011., stage I;, stage II;, stage III;,stage IV;, unknown;, neoadjuvant hemotherapy. Figure 8 Distribution of surgical stages in patients with ovarian cancer in Figure 9 Distribution of treatment methods in patients with ovarian cancer by surgical stage in 2011., stage I;, stage II;,stage III;, stage IV;, unknown;, neoadjuvant hemotherapy The Author
6 Annual report of gynecologic cancers in Japan Table 3 Histological types of ovarian cancer in 2011 Histological type No. of % patients Serous adenocarcinoma Mucinous adenocarcinoma Endometrioid adenocarcinoma Clear cell adenocarcinoma Undifferentiated carcinoma Mixed-type adenocarcinoma Adenosarcoma (homologous) Adenosarcoma (heterologous) Mesodermal mixed tumor (homologous) Mesodermal mixed tumor (heterologous) Stromal sarcoma Malignant Brenner tumor Transitional cell carcinoma Unclassifiable Others Sertoli-stromal cell tumor (poorly differentiated) Fibrosarcoma Others Immature teratoma G Dysgerminoma Yolk sac tumor Malignant mixed germ cell tumor Malignant mixed germ cell tumor: yolk sac tumor+dysgerminoma Malignant mixed germ cell tumor: yolk sac tumor+immature teratoma Malignant mixed germ cell tumor: others Mature cystic teratoma with malignant transformation Embryonal carcinoma Polyembryoma Choriocarcinoma Others Sarcoma Carcinoma of the rete ovarii Small cell carcinoma Hepatoid carcinoma Squamous cell carcinoma Gestational choriocarcinoma Malignant lymphoma (primary) Unclassifiable Tumor possibly originating from the Wolffian duct Others Total Ovarian tumors of borderline malignancy Surgical stages (Fig. 10). Stage I accounted for 93.0% (stage Ia, 65.0%; stage Ib, 2.3%; stage Ic, 25.7%), stage II for 1.8% (stage IIa, 0.2%; stage IIb, 0.5%; stage IIc, 1.1%), stage III for 4.5% (stage IIIa, 1.0%; stage IIIb, 1.1%; stage IIIc, 2.4%), and stage IV for 0.4% of all the patients. Neoadjuvant chemotherapy was given to 0.4% of the patients. Histological types (Table 4). Mucinous tumors accounted for 59.2%, serous tumors for 21.2%, endometrioid tumors for 2.3%, and mixed tumors for 2.3% of all the tumors. In addition, granulosa cell tumors accounted for 6.5% and immature teratomas (G1, G2) for 2.9% of the tumors. Treatment (Fig. 11). Of the patients, 93.0% underwent surgery alone, and 6.9% received chemotherapy after surgery. Treatment Annual Report in Cervical cancer Overall survival by clinical stage (Fig. 12). The overall survival rates by clinical stage are shown in Figure The Author 343
7 D. Aoki Figure 10 Distribution of surgical stages in patients with ovarian tumor of borderline malignancy in Figure 11 Distribution of treatment methods in patients with ovarian tumor of borderline malignancy by surgical stage in 2011., stage I;, stage II;, stage III;, stage IV;, unknown;, neoadjuvant hemotherapy. Table 4 Histological types of ovarian tumor of borderline malignancy Histological type No. of % patients Serous tumor Mucinous tumor Endometrioid tumor Clear cell tumor Proliferating Brenner tumor Mixed tumor Unclassifiable Others Granulosa cell tumor Sertoli-stromal cell tumor (moderately differentiated) Gynandroblastoma Steroid cell tumor (unclassifiable) Others Immature teratoma (G1, G2) Carcinoid Neuroectodermal tumor Others Tumor of borderline malignancy other than the above: gonadoblastoma Tumor of borderline malignancy other than the above: mixed germ cell sex cord-stromal tumor Tumor of borderline malignancy other than the above: others Total The Author
8 Annual report of gynecologic cancers in Japan Figure 12 Overall survival in patients with stage I IV cervical cancer by clinical stage in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. Figure 13 Overall survival in patients with stage I IV cervical cancer by histological type in Log rank P < , squamous carcinoma;, adenosquamous carcinoma;, adenocarcinoma;, others. The 5-year overall survival rates were 91.3% in stage I patients (stage Ia1, 98.9%; stage Ia2, 100%; stage Ib1, 90.8%; stage Ib2, 79.0%), 77.8% in stage II patients (stage IIa, 86.7%; stage IIb, 73.9%), 56.9% in stage III patients (stage IIIa, 68.0%; stage IIIb, 56.2%), and 30.1% in stage IV patients (stage IVa, 42.7%; stage IVb, 22.7%). There were significant differences between stages I and II (P < 0.001), stages II and III (P < 0.001), and stages III and IV (P = 0.003). Overall survival by histological type (Fig. 13). The overall survival rates by the histological type are shown in Figure 13. The 5-year overall survival rates were 80.4%, 75.7%, 74.0%, and 59.4% in patients with squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and other cancers, respectively. Patients with squamous cell carcinoma had a significantly better prognosis than those with adenocarcinoma (P = 0.004), adenosquamous carcinoma (P < 0.001), and other cancers (P < 0.001). 2. Endometrial cancer Overall survival by surgical stage (Fig. 14). The overall survival rates by surgical stage are shown in Figure 14. The 5-year overall survival rates were 95.1% in stage I patients (stage Ia, 97.6%; stage Ib, 95.9%; stage Ic, 89.7%), 89.2% in stage II patients (stage IIa, 91.2%; stage IIb, 88.9%), 76.8% in stage III patients (stage IIIa, 85.3%; stage IIIb, 42.4%; stage IIIc, 23.1%), and 23.1% in stage 2014 The Author 345
9 D. Aoki Figure 14 Overall survival in patients with stage I IV endometrial cancer by surgical stage in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. Table 5 Five-year survival rates of endometrial cancer patients by stage and histological type FIGO Stage Histology Patients treated 5-year survival No. % % I Endometrioid type Serous, Mucinous, Clear cell type Others No description II Endometrioid type Serous, Mucinous, Clear cell type Others No description III Endometrioid type Serous, Mucinous, Clear cell type Others No description IV Endometrioid type Serous, Mucinous, Clear cell type Others No description FIGO, International Federation of Obstetricians and Gynaecologists. IV patients (stage IVa, 45.5%; stage IVb, 20.7%). There were significant differences between stages I and II (P < 0.001), stages II and III (P < 0.001), or stages III and IV (P < 0.001). Overall survival by histological type (Table 5). The 5-year overall survival rates were 95.6%, 88.9%, and 76.1% in patients with G1, G2, and G3 endometrioid adenocarcinoma, respectively. Comparison of the survival among the stages revealed 5-year overall survival rates of 96.5%, 87.7% and 86.6% in patients with stage I endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histological types, respectively; 91.9%, 77.4% and 77.2% in patients with stage II endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histological types, respectively; 83.6%, 54.8% and 64.3% in patients with stage III endometrioid carcinoma, serous/mucinous/clear adenocarcinoma and other histological types, respectively; and 25.6%, 19.4%, and 20.5% in patients with The Author
10 Annual report of gynecologic cancers in Japan Figure 15 Overall survival in patients with ovarian cancer by surgical stage in Log rank P < , International Federation of Gynecology and Obstetrics (FIGO) stage I;, FIGO stage II;, FIGO stage III;, FIGO stage IV. Figure 16 Overall survival in patients with ovarian cancer by histological type in Log rank P < , serous;, mucinous;, endometrioid;, clear;, other. stage IV endometrioid carcinoma, serous/mucinous/ clear adenocarcinoma and other histological types, respectively. 3. Ovarian cancer Overall survival by surgical stage (Fig. 15). The overall survival rates by surgical stage are shown in Figure 15. When compared among stages of surface epithelialstromal tumors, the 5-year overall survival rates were 91.7% in stage I patients (stage Ia, 93.1%; stage Ib, 100%; stage Ic(b), 91.9%; stage Ic(1), 88.9%; stage Ic(2), 87.2%; stage Ic(a), 90.2%), 74.8% in stage II patients (stage IIa, 81.8%; stage IIb, 76.9%; stage IIc(b), 79.6%; stage IIc(1), 85.7%; stage IIc(2), 72.7%; stage IIc(a), 67.0%), 49.6% in stage III patients (stage IIIa, 82.4%; stage IIIb, 69.4%; stage IIIc, 45.6%), and 38.6% in stage IV patients. There were significant differences between stages I and II (P < 0.001), stages II and III (P < 0.001), and stages III and IV (P < 0.001). The above analysis did not include patients who received neoadjuvant chemotherapy, and the 5-year overall survival rate of the patients who received neoadjuvant chemotherapy was 37.1%. Overall survival by histological type (Fig. 16). The overall survival rates by the histological type are shown in Figure 16. Patients with serous adenocarcinoma had a significantly poorer prognosis than those with 2014 The Author 347
11 D. Aoki mucinous adenocarcinoma (P < 0.001), endometrioid adenocarcinoma (P < 0.001) and clear cell adenocarcinoma (P < 0.001). Discussion The FIGO 1988 staging classification was adopted for this statistical analysis of cervical, endometrial and ovarian cancers. In regard to the clinical staging of cervical cancer, the diagnosis of stage I cervical cancer is influenced by the type of specimen examined, that is, cervical biopsy, cervical conization or total hysterectomy specimens, and it is expected that there may be differences in the interpretation among institutions as well. In addition, stage IVb is also interpreted differently among institutions, and it is possible that some patients may have been diagnosed as having stage IVb due to the presence of distant metastases or para-aortic lymphadenopathy on CT and other imaging diagnosis. In the analysis of endometrial and ovarian cancers, surgical staging classification was adopted and the diagnosis without surgery was performed only in a small number of cases comprising 4.5% and 2.1% of patients with endometrial and ovarian cancer, respectively. This suggested that summarized distribution of the surgical stages was still reliable. In regard to the histological types, there is a problem not in cervical, endometrial cancers or ovarian surface epithelial-stromal tumors, but in ovarian sex cordstromal and germ cell tumors: there are a small number of patients with these ovarian tumors and only an insufficient number of cases can be accumulated in a year. Therefore, the influence even from a single case can be large, leading to over- or under-estimation. Consequently, it seems impossible to compare and analyze the changes over time. Prognosis was analyzed by the Kaplan Meier method. Terminal-stage patients are often transferred to other medical institutions in Japan, and in such cases, information on the patients cannot often be obtained after hospital transfer, which leads to unknown prognosis. Fatal cases are considered to account for most of these prognosis-unknown cases. Therefore, if all these prognosis-unknown cases are counted as alive dropouts, the prognosis may be better estimated even by the Kaplan Meier method. Accordingly, in the present study, information from institutions in which the prognosis was untraceable for 20% or more of the cases was excluded from the analysis. Among the patients with known prognosis, 58.7% of patients with cervical cancer, 65.9% of patients with endometrial cancer, and 60.0% of patients with ovarian cancer were included in the analysis of the prognosis. However, in this method of analysis, it tends to be more difficult to collect information on patients from larger medical institutions, and future investigations are considered necessary to allow more accurate information on the prognosis to be reflected in the Treatment Annual Reports. Conclusion The Patient Annual Report and Treatment Annual Report on gynecologic tumors (cervical, endometrial, and ovarian cancers and ovarian tumors of borderline malignancy) in Japan are presented in this paper. Acknowledgment The author thanks the member institutions of the Japan Society of Obstetrics and Gynecology for its cooperation in providing data on patients with gynecologic tumors, and the Biostatistics Center, Kurume University for the data analysis. The author also thanks all members of the committee on gynecologic oncology of the Japan Society of Obstetrics and Gynecology and Dr Wataru Yamagami in the Department of Obstetrics and Gynecology, School of Medicine, Keio University for their contribution to summarizing the data and Ms Miyuki Nakai and Ms Keiko Abe for their secretarial help. Disclosure There is no conflict of interest. References 1. Aoki Y. The Patient Annual Report in Acta Obstet Gynaecol Jpn 2012; 64: Aoki Y. The Treatment Annual Report in Acta Obstet Gynaecol Jpn 2013; 65: The Author
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
More informationClinical statistics of gynecologic cancers in Japan
J Gynecol Oncol. 2017 Mar;28(2):e32 pissn 2005-0380 eissn 2005-0399 Review Article Clinical statistics of gynecologic cancers in Japan Wataru Yamagami, 1,7 Satoru Nagase, 2,7 Fumiaki Takahashi, 3 Kazuhiko
More informationSpringer Healthcare. Understanding and Diagnosing Ovarian Cancer. Concise Reference: Krishnansu S Tewari, Bradley J Monk
Concise Reference: Understanding and Diagnosing Ovarian Cancer Krishnansu S Tewari, Bradley J Monk Extracted from: The 21 st Century Handbook of Clinical Ovarian Cancer Published by Springer Healthcare
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationType I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53
Type I Excess estrogen Lynch Endometrioid adenocarcinoma PTEN Type II High grade More aggressive Serous, Clear Cell p53 Stage I IA IB Stage II Stage III IIIA IIIB IIIC IIIC1 IIIC2 Stage IV IVA IVB nodes
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More information3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal cells
More informationL/O/G/O. Ovarian Tumor. Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital
L/O/G/O Ovarian Tumor Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital Essentials classification of ovarian tumor clinical manifestation of ovarian tumor metastatic
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationAnalysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix
DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department
More informationVulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact Dermatitis Psoriasis Lichen Simplex Chronicus Foreign Body
More informationInstitute of Pathology First Faculty of Medicine Charles University. Ovary
Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction
More informationPathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh
Pathology of Ovarian Tumours Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh Outline Incidence Risk factors Classification Pathology of tumours Tumour markers Prevention
More informationICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31
R=Rare Tier Tumour ICD-O Topography code ICD-O Morphology code EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses C30.0, C3 C30.0, C3 8000,
More informationCarcinoma of the Fallopian Tube
119 Carcinoma of the Fallopian Tube APM HEINTZ, F ODICINO, P MAISONNEUVE, U BELLER, JL BENEDET, WT CREASMAN, HYS NGAN and S PECORELLI STAGING Anatomy Primary site The Fallopian tube extends from the posterior
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationHISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD
HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE 2000-2009 PERIOD Gheorghe Furău 1), Voicu Daşcău 1), Cristian Furău 1), Lucian
More informationSee the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.
About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What Is
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationGynaecological Malignancies
Gynaecological Malignancies Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea Division of Pathology School of Medicine & Health Sciences Overview Genital tract tumors
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationOvarian Tumors: A Study of 2146 Cases at AFIP, Rawalpindi, Pakistan.
Ovarian Tumors: A Study of 2146 Cases at AFIP, Rawalpindi, Pakistan. 1 Muhammad Zubair, 2 Shoaib Naiyar Hashmi, 3 Saeed Afzal, 4 Iqbal Muhammad, 5 Hafeez Ud Din, 6 Syed Naeem Raza Hamdani, 7 Rabia Ahmad.
More informationAn Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases
Anatomic Pathology / CYTOLOGY OF CARCINOSARCOMA OF UTERUS An Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases Matthew J. Snyder, MD, 1
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationDr Sanjiv Manek Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Sanjiv Manek Oxford Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust Ovarian Endometrial Vulvo-vaginal Cervical Illustration-Cellular Pathology. Oxford
More informationOVARIES. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb.
OVARIES MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb. OBJECTIVES Recognize different disease of ovaries Classify ovarian cyst Describe the pathogenesis, morphology
More informationStage 3 ovarian cancer survival rate
Search Stage 3 ovarian cancer survival rate 19-5-2017 If you've been diagnosed with ovarian cancer, it's natural to wonder about your prognosis. Learn about survival rates, outlook, and more. Take the
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationStage 3 ovarian cancer survival rate
Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationOppgave: MED5600_OPPGAVE04_V18_ORD
Side 23 av 63 Oppgave: MED5600_OPPGAVE04_V18_ORD Del 1: Sofie, 38 years, para1, comes to your office complaining about dyspareunia and spotting she has recently observed on several occasions, unrelated
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationCytology and Surgical Pathology of Gynecologic Neoplasms
Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632
More informationUterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!
Uterine October 7, 2010 NAACCR 2010-2011 Webinar Series Session 1 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes!!! 3 NAACCR 2010-2011 Webinar
More informationGynecologic Malignancies. Kristen D Starbuck 4/20/18
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
More informationAdenocarcinoma of the Cervix
Question 1. Each of the following statements about cervical adenocarcinoma is true except: Adenocarcinoma of the Cervix SAMS a) A majority of women with cervical adenocarcinoma have stage I tumors at diagnosis.
More informationEndometrial cancer in women 45 years of age or younger: A clinicopathological analysis
American Journal of Obstetrics and Gynecology (2005) 193, 1640 4 www.ajog.org Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis Gilbert P. Pellerin, MD, Michael A.
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationARRO Case: Early-stage Endometrial Cancer
ARRO Case: Early-stage Endometrial Cancer Ankit Modh, MD (PGY-4) Faculty Advisor: Mohamed A Elshaikh, MD Department of Radiation Oncology Henry Ford Cancer Institute Case Presentation 70 y/o African American
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationAtypical Hyperplasia/EIN
EIN Atypical Hyperplasia/EIN Based on scientific and diagnostic advances, in 2014 the WHO moved that the precursor lesion for endometrioid carcinoma be atypical hyperplasia/ein, rather than what was previously
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
More informationCase 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst
Gynaecology Case Presentation Organ Imaging 2016 University of Toronto Sarah Johnson 39 year old female Clinical history: Assess right ovarian cyst Clinically diagnosed endometriosis Started fertility
More informationDiagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis
Original Article Diagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis Neha Gupta 1*, Poonam Gupta 2, Omvati Gupta
More informationJournal of Rawalpindi Medical College (JRMC); 2016;20(4):
Original Article Morphological Profile of Ovarian Tumours Bilquis Begum, Iram Nadeem Rana, Nadeem Ikram Department of Pathology, Rawalpindi Medical College, Rawalpindi Abstract Background: To study the
More informationMalignant transformation in benign cystic teratomas, dermoids of the ovary
European JournalofObstetrics& Gynecology andreproductivebiology, 29 (1988) 197-206 197 Elsevier EJO 00716 Malignant transformation in benign cystic teratomas, dermoids of the ovary S. Chadha 1 and A. Schaberg
More informationORIGINAL ARTICLE CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL
CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL Madhuri Kulkarni 1, Ambarish Bhandiwad 2, Sunila R 3, Sumangala 4. 1. Professor, Department
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationSTUMPed for a Diagnosis Contemporary Management of Uterine Sarcomas
UCSF Helen Diller Family Comprehensive Cancer Center Disclosures I have no financial disclosures STUMPed for a Diagnosis Contemporary Management of Uterine Sarcomas Lee-may Chen, MD Department of Obstetrics,
More informationNAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationPort-Site Metastases After Robotic Surgery for Gynecologic Malignancy
SCIENTIFIC PAPER Port-Site Metastases After Robotic Surgery for Gynecologic Malignancy Noah Rindos, MD, Christine L. Curry, MD, PhD, Rami Tabbarah, MD, Valena Wright, MD ABSTRACT Background and Objectives:
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More information2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
More informationAdenocarcinoma of the Endometrium: An Institutional Review
Pieter Baltens, 1580. Feast of St. George. From the collection of Dr. Gordon and Adele Gilbert of St. Petersburg, Florida. Adenocarcinoma of the Endometrium: An Institutional Review Denis Cavanagh, MD;
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThis protocol is intended to assist pathologists in providing
Protocol for the Examination of Specimens From Patients With Carcinomas of the Endometrium A Basis for Checklists Steven G. Silverberg, MD, for the Members of the Cancer Committee, College of American
More informationPathology of the female genital tract
Pathology of the female genital tract Common illnesses of the female genital tract Before menarche Developmental anomalies Tumors (ovarial teratoma) Amenorrhea Fertile years PCOS, ovarian cysts Endometriosis
More informationIndex. Cytoplasm, nonepithelial malignant tumor features 70
Accurette device 23 Adenosarcoma, differential diagnosis 80, 81 Arias-Stella reaction 65 Atypical endocervical cells 8 Atypical endometrial cells 8 Atypical glandular cells (AGC) 8, 9 Atypical glandular
More information2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA
2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationSarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru
Sarah Burton Lead Gynae Oncology Nurse Specialist Cancer Care Cymru Gynaecological Cancers Cervical Cancers Risk factors Presentation Early sexual activity Multiple sexual partners Smoking Human Papiloma
More informationS2199 S2200. * Speaker's diagnosis 78
98 21 2 14 13:30 * Speaker's diagnosis 78 S2199 Meningioma 48 Papillary meningioma * 30 Angiomatous meningioma 15 Ependymoma 12 Papillary ependymoma 6 Anaplastic ependymoma 2 Cellular ependymoma 1 Hemangioblastoma
More informationIncidence, Histological Types and Age at Presentation of Borderline and Malignant Ovarian Tumors at a Tertiary Institute in Nepal
NJOG 01 Jul-Dec; 18 ():11-16 Original Article Incidence, Histological Types and Age at Presentation of Borderline and Malignant Ovarian Tumors at a Tertiary Institute in Nepal Deptartment of Obstetrics
More informationClinicopathological and Histological Features of Ovarian Tumour- A Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 9 Ver. IX (September. 2017), PP 56-60 www.iosrjournals.org Clinicopathological and Histological
More informationProtocol for the Examination of Lymphadenectomy Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis
Protocol for the Examination of Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis Version: Testis 4.0.1.1 Protocol Posting Date: February 2019 Accreditation Requirements
More informationAlgorithms for management of Cervical cancer
Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationHistopathological Study of Ovarian Lesions
Histopathological Study of Ovarian Lesions Nirali N. Thakkar 1, Shaila N. Shah 2 1 Resident doctor, Pathology department, Government Medical College, Bhavnagar-364001, India 2 Head of the department, Pathology
More informationVULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
More informationUterus Malignancies /5/15
Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More informationCytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium
Jpn J Clin Oncol 2003;33(12)636 641 Cytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium Yukiharu Todo, Shinichirou Minobe, Kazuhira Okamoto, Mahito Takeda, Yasuhiko Ebina,
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationJanjira Petsuksiri, M.D
GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors
More informationThe new FIGO classification in endometrial carcinoma
The new FIGO classification in endometrial carcinoma Poster No.: C-1073 Congress: ECR 2012 Type: Educational Exhibit Authors: A. IGLESIAS CASTAÑON, M. Arias Gonzales, J. Mañas Uxó, 1 2 1 2 2 2 B. NIETO
More informationuterine cancer endometrial cancer
2018 ICD-10-CM Diagnosis Code. Adenocarcinoma of endometrium ; Cancer of the. (mucous membrane that lines the endometrial cavity). ICD-10-CM C54.1 is grouped. Home ICD 9 Codes Endometrial Cancer ICD 9
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationCase Report Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor
Case Reports in Obstetrics and Gynecology Volume 2015, Article ID 612824, 5 pages http://dx.doi.org/10.1155/2015/612824 Case Report Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor
More informationSurvival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran
ORIGINAL ARTICLE Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran Katayoun Ziari, Ebrahim Soleymani, and
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationChristian Marth, MD, PhD Department of Obstetrics and Gynecology Innsbruck Medical University Innsbruck, Austria
Christian Marth, MD, PhD Department of Obstetrics and Gynecology Innsbruck Medical University Innsbruck, Austria Classification of Ovarian Neoplasms Origin Surface Epithelial Cells Germ Cells Sex Cord
More informationGUIDELINES ON TESTICULAR CANCER
38 (Text updated March 2005) P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, O. Klepp, M.P. Laguna, G. Pizzocaro Introduction Compared with other types of cancer
More informationHistopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases
Orginal Article Histopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases 2 G Prathima, Srikanth Shastry 2 Consultant Pathologist, Image Diagnostics, Kadapa,
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More information